Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 3
2001 4
2002 4
2003 4
2004 4
2005 8
2006 4
2007 4
2008 4
2009 4
2010 5
2011 4
2012 3
2013 9
2014 3
2015 2
2016 7
2017 11
2018 7
2019 5
2020 9
2021 5
2022 6
2023 3
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Rohaan MW, et al. Among authors: nuijen b. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. N Engl J Med. 2022. PMID: 36477031 Clinical Trial.
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, de Boer R, Bakker NAM, Jorritsma-Smit A, van Buuren MM, Kvistborg P, Spits H, Schotte R, Mallo H, Karger M, van der Hage JA, Wouters MWJM, Pronk LM, Geukes Foppen MH, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. van den Berg JH, et al. Among authors: nuijen b. J Immunother Cancer. 2020 Aug;8(2):e000848. doi: 10.1136/jitc-2020-000848. J Immunother Cancer. 2020. PMID: 32753545 Free PMC article. Clinical Trial.
Inherent formulation issues of kinase inhibitors.
Herbrink M, Schellens JH, Beijnen JH, Nuijen B. Herbrink M, et al. Among authors: nuijen b. J Control Release. 2016 Oct 10;239:118-27. doi: 10.1016/j.jconrel.2016.08.036. Epub 2016 Aug 28. J Control Release. 2016. PMID: 27578098 Review.
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT, Rohaan MW, Jedema I, Kessels R, Stegeman W, Scheepmaker W, Nuijen B, Nijenhuis C, Lindenberg M, Borch TH, Monberg T, Donia M, Marie Svane I, van Harten W, Haanen J, Retel VP. Ten Ham RMT, et al. Among authors: nuijen b. J Immunother Cancer. 2024 Mar 26;12(3):e008372. doi: 10.1136/jitc-2023-008372. J Immunother Cancer. 2024. PMID: 38531663 Free PMC article. Clinical Trial.
Taxanes: old drugs, new oral formulations.
Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Jibodh RA, et al. Among authors: nuijen b. Eur J Pharmacol. 2013 Oct 5;717(1-3):40-6. doi: 10.1016/j.ejphar.2013.02.058. Epub 2013 May 7. Eur J Pharmacol. 2013. PMID: 23660368 Review.
High-Tech Drugs in Creaky Formulations.
Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. Herbrink M, et al. Among authors: nuijen b. Pharm Res. 2017 Sep;34(9):1751-1753. doi: 10.1007/s11095-017-2185-4. Epub 2017 May 30. Pharm Res. 2017. PMID: 28560695
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R. Wang L, et al. Among authors: nuijen b. Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10. Cell. 2018. PMID: 29754815 Free article.
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.
Embaby A, Huijberts SCFA, Wang L, Leite de Oliveira R, Rosing H, Nuijen B, Sanders J, Hofland I, van Steenis C, Kluin RJC, Lieftink C, Smith CG, Blank CU, van Thienen JV, Haanen JBAG, Steeghs N, Opdam FL, Beijnen JH, Huitema ADR, Bernards R, Schellens JHM, Wilgenhof S. Embaby A, et al. Among authors: nuijen b. Clin Cancer Res. 2024 Aug 1;30(15):3157-3166. doi: 10.1158/1078-0432.CCR-23-3171. Clin Cancer Res. 2024. PMID: 38739109
114 results